Rigor Reviewed

Rigor-Reviewed Manuscript

A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.

Name: Αlpha¹ Rigor Record — A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.
Item: A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.
Rating: 96
Author: Αlpha¹

Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, Chisele S, Shibemba AL, Sauvaget C, Sankaranarayanan R, Prendiville W, Parham GP

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 3 high issues for “A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized noninferiority trial with strong methodology across most dimensions. The main weakness is the vague data and code availability statements, which lack a concrete repository or managed-access platform. Minor copyediting issues in Table 5 (point estimates inconsistent with confidence intervals) warrant correction.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence to reconcile. The statistics verification component recomputed only 2 tests (1 consistent, 0 inconsistent) due to limited coverage; most reported statistics remain unverified. The citation check found no retracted or unresolved references. The reproducibility check confirmed the one link is live.

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites WHO guidelines and prior studies on cryotherapy and LLETZ, acknowledges the lack of RCT evidence for TA, and explains the need for the trial. The rationale links the evidence gap to the study objectives, and the limitations of prior research (e.g., conditional WHO recommendation based on low certainty) are explicitly addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise, citing prior work and guidelines, and provides a logical rationale for the trial.

Evidence

paraphrase[Introduction, paragraph 1]

“The ‘screen-and-treat’ approach... is a well-accepted protocol in cervical screening programs in low- and middle-income countries (LMICs). The strategy has been endorsed in the latest guideline published by the World Health Organization (WHO) in 2021”

paraphrase[Introduction, paragraph 3]

“Despite these advantages, the 2019 WHO recommendation was ‘conditional’ and based on ‘very low certainty in evidence of effects’ given the lack of evidence from any randomized controlled trial (RCT) directly comparing the two treatment strategies in screen-and-treat settings.”

paraphrase[Discussion, paragraph 4]

“In their meta-analysis of 13 studies evaluating TA, Dolman et al. reported a high cure rate of 95%... None had any data on women who were HIV positive. The results from our large prospective RCT provide much needed evidence on the noninferiority of efficacy of TA compared to cryotherapy or LLETZ”

PASSReviewer 2· 90% conf

The study clearly establishes the scientific premise, citing prior work and guidelines, and provides a logical rationale for the trial.

Evidence

paraphrase[Main, paragraph 1]

direct quote[Main, paragraph 2]

“the 2019 WHO recommendation was ‘conditional’ and based on ‘very low certainty in evidence of effects’ given the lack of evidence from any randomized controlled trial (RCT) directly comparing the two treatment strategies”